Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data

M. Campioni, I. Agirrezabal, R. Hajek, J. Minarik, L. Pour, I. Spicka, S. Gonzalez-McQuire, P. Jandova, V. Maisnar,

. 2020 ; 21 (2) : 219-233. [pub] 20191031

Language English Country Germany

Document type Journal Article, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc20028433

OBJECTIVE: To predict the real-world (RW) cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in relapsed multiple myeloma (MM) patients after one to three prior therapies. METHODS: A partitioned survival model that included three health states (progression-free, progressed disease and death) was built. Progression-free survival (PFS), overall survival (OS) and time to discontinuation (TTD) data for the Rd arm were derived using the Registry of Monoclonal Gammopathies in the Czech Republic; the relative treatment effects of KRd versus Rd were estimated from the phase 3, randomised, ASPIRE trial, and were used to predict PFS, OS and TTD for KRd. The model was developed from the payer perspective and included drug costs, administration costs, monitoring costs, palliative care costs and adverse-event related costs collected from Czech sources. RESULTS: The base case incremental cost effectiveness ratio for KRd compared with Rd was €73,156 per quality-adjusted life year (QALY) gained. Patients on KRd incurred costs of €117,534 over their lifetime compared with €53,165 for patients on Rd. The QALYs gained were 2.63 and 1.75 for patients on KRd and Rd, respectively. CONCLUSIONS: Combining the strengths of randomised controlled trials and observational databases in cost-effectiveness models can generate policy-relevant results to allow well-informed decision-making. The current model showed that KRd is likely to be cost-effective versus Rd in the RW and, therefore, the reimbursement of KRd represents an efficient allocation of resources within the healthcare system.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028433
003      
CZ-PrNML
005      
20210114153840.0
007      
ta
008      
210105s2020 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10198-019-01122-6 $2 doi
035    __
$a (PubMed)31673898
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Campioni, M $u Economic Modeling Center of Excellence, Global Health Economics, Amgen (Europe) GmbH, Zug, Switzerland. campioni@amgen.com.
245    10
$a Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data / $c M. Campioni, I. Agirrezabal, R. Hajek, J. Minarik, L. Pour, I. Spicka, S. Gonzalez-McQuire, P. Jandova, V. Maisnar,
520    9_
$a OBJECTIVE: To predict the real-world (RW) cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in relapsed multiple myeloma (MM) patients after one to three prior therapies. METHODS: A partitioned survival model that included three health states (progression-free, progressed disease and death) was built. Progression-free survival (PFS), overall survival (OS) and time to discontinuation (TTD) data for the Rd arm were derived using the Registry of Monoclonal Gammopathies in the Czech Republic; the relative treatment effects of KRd versus Rd were estimated from the phase 3, randomised, ASPIRE trial, and were used to predict PFS, OS and TTD for KRd. The model was developed from the payer perspective and included drug costs, administration costs, monitoring costs, palliative care costs and adverse-event related costs collected from Czech sources. RESULTS: The base case incremental cost effectiveness ratio for KRd compared with Rd was €73,156 per quality-adjusted life year (QALY) gained. Patients on KRd incurred costs of €117,534 over their lifetime compared with €53,165 for patients on Rd. The QALYs gained were 2.63 and 1.75 for patients on KRd and Rd, respectively. CONCLUSIONS: Combining the strengths of randomised controlled trials and observational databases in cost-effectiveness models can generate policy-relevant results to allow well-informed decision-making. The current model showed that KRd is likely to be cost-effective versus Rd in the RW and, therefore, the reimbursement of KRd represents an efficient allocation of resources within the healthcare system.
650    _2
$a protokoly protinádorové kombinované chemoterapie $7 D000971
650    12
$a analýza nákladů a výnosů $7 D003362
650    _2
$a dexamethason $x farmakologie $7 D003907
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a náklady na léky $7 D016527
650    _2
$a lidé $7 D006801
650    _2
$a lenalidomid $x farmakologie $7 D000077269
650    _2
$a mnohočetný myelom $x farmakoterapie $x etiologie $x mortalita $7 D009101
650    _2
$a lokální recidiva nádoru $x farmakoterapie $x etiologie $7 D009364
650    _2
$a oligopeptidy $x farmakologie $7 D009842
650    _2
$a kvalitativně upravené roky života $7 D019057
650    _2
$a registrace $7 D012042
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Agirrezabal, I $u Economic Modeling Center of Excellence, Global Health Economics, Amgen (Europe) GmbH, Zug, Switzerland.
700    1_
$a Hajek, R $u Department of Haematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, 17. listopadu 1790, 708 52, Ostrava, Czech Republic.
700    1_
$a Minarik, J $u Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, I. P. Pavlova 185/6, 779 00, Olomouc, Czech Republic.
700    1_
$a Pour, L $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine Masaryk Universit, Jihlavská 340/20, 625 00, Brno, Czech Republic.
700    1_
$a Spicka, I $u Department of Internal Medicine, Charles University in Prague, First Faculty of Medicine and General Teaching Hospital, Katerinska 32, 121 08, Prague, Czech Republic.
700    1_
$a Gonzalez-McQuire, S $u Global Health Economics, Amgen (Europe) GmbH, Zug, Switzerland.
700    1_
$a Jandova, P $u Amgen s.r.o, Prague, Czech Republic.
700    1_
$a Maisnar, V $u Department of Internal Medicine, Charles University in Prague, First Faculty of Medicine and General Teaching Hospital, Katerinska 32, 121 08, Prague, Czech Republic.
773    0_
$w MED00007432 $t The European journal of health economics : HEPAC : health economics in prevention and care $x 1618-7601 $g Roč. 21, č. 2 (2020), s. 219-233
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31673898 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114153837 $b ABA008
999    __
$a ok $b bmc $g 1608768 $s 1119613
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 21 $c 2 $d 219-233 $e 20191031 $i 1618-7601 $m The European journal of health economics $n Eur J Health Econ $x MED00007432
LZP    __
$a Pubmed-20210105
Back

Find record

Citation metrics

Archiving options